0001178913-18-001598.txt : 20180510 0001178913-18-001598.hdr.sgml : 20180510 20180510173056 ACCESSION NUMBER: 0001178913-18-001598 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180508 FILED AS OF DATE: 20180510 DATE AS OF CHANGE: 20180510 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Domzalski David CENTRAL INDEX KEY: 0001727794 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36621 FILM NUMBER: 18824210 MAIL ADDRESS: STREET 1: C/O FOAMIX PHARMACEUTICALS LTD. STREET 2: 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Foamix Pharmaceuticals Ltd. CENTRAL INDEX KEY: 0001606645 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 HOLZMAN ST. STREET 2: WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 BUSINESS PHONE: 97289316233 MAIL ADDRESS: STREET 1: 2 HOLZMAN ST. STREET 2: WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 FORMER COMPANY: FORMER CONFORMED NAME: Foamix Ltd. DATE OF NAME CHANGE: 20140428 4 1 zk1821661.xml OWNERSHIP DOCUMENT X0306 4 2018-05-08 0 0001606645 Foamix Pharmaceuticals Ltd. FOMX 0001727794 Domzalski David C/O FOAMIX PHARMACEUTICALS LTD. 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK REHOVOT L3 76704 ISRAEL 1 1 0 0 CEO Ordinary Shares 2018-05-08 4 A 0 23396 0.00 D 163150 D Options 5.06 2018-05-08 4 A 0 70187 0 A 2028-02-27 Ordinary Shares 70187 70187 D The equity incentive grants were approved by the Issuer's board of directors on the recommendation of a committee of the board on February 27, 2019, subject to shareholder approval as required under the Israeli Companies Law. The Issuer's shareholders approved the equity incentive grants on May 8, 2018. The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022. This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. Each option represents a contingent right to purchase one ordinary share of the issuer. The ordinary shares underlying these options vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022. /s/ Ilan Hadar as attorney-in-fact for David Domzalski 2018-05-10